Study Summary
This is a first-in-human trial proposed to test CD19-specific CAR-T cells with edited endogenous HPK1 (XYF19 CAR-T cells) in patients with relapsed or refractory CD19+ leukemia or lymphoma. This is an investigational study designed as a single-center, open-label and single-arm clinical trial.
Want to learn more about this trial?
Request More InfoInterventions
XYF19 CAR-T cellGENETIC
Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
CyclophosphamideDRUG
A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
FludarabineDRUG
A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Xijing Hospital | Xi'an | Shannxi | China |